Reprieve Cardiovascular emerged this week, announcing a hefty $42M Series A round and an even bigger mission to “transform the standard of care” for patients with acute decompensated heart failure.
Founded in 2020 and operating in stealth before now, Reprieve Cardiovascular is developing an intelligent automated diuretic and fluid management system for ADHF treatment.
The Reprieve System is designed to monitor ADHF patients and deliver personalized diuretic dosing and fluid replacement, while giving physicians real-time insights to help them optimize patient care. More specifically, The Reprieve System is meant to allow care teams to…
- Find the Right Dose, Fast – by measuring and analyzing urine output, and optimizing patients’ diuretic dose in the first hour.
- Maintain The Right Dosing – by recommending when to escalate/end therapy.
- Keep the Kidney Happy and Control Diuretic Resistance – by continuously titrating saline replacement (when needed) to maximize urine output and maintain renal function.
That approach could get HF care teams’ attention, given that even after 60 years of clinical use, diuretic optimization can still be a challenge without real-time visibility into patient information. Plus, fluid volume overload still causes 25% of discharged HF patients to be readmitted within 30 days.
To meet this clinical need and prove its capabilities, Reprieve Cardiovascular is targeting its new funding towards its clinical and development programs, including the ongoing FASTR pilot trial (compares Reprieve vs. standard diuretic therapy) and its upcoming pivotal trial.
The Takeaway
We don’t see many diuretic and fluid management startups emerging these days, but given acute ADHF patients’ lengthy hospital stays and significant readmission risks, there’s certainly room for innovation in this space. Reprieve Cardiovascular still has lots to prove, but its combination of automated monitoring, dosing, and fluid replacement could end up being the innovation that ADHF patients and their providers have been looking for.
